James A Donegan

US Patent:

20210302445, Sep 30, 2021

Filed:

Apr 14, 2021

Appl. No.:

17/229939

Inventors:

- Farmingdale NY, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US
WAYNE FORREST PATTON - DIX HILLS NY, US
JAMES J. DONEGAN - AMESBURY MA, US

Assignee:

ENZO LIFE SCIENCES, INC. - Farmingdale NY

International Classification:

G01N 33/92
C07J 9/00
C07J 43/00
C07K 16/44
G01N 33/569
G01N 33/53
C07K 16/18

Abstract:

Provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Still further provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.

US Patent:

20190383839, Dec 19, 2019

Filed:

Dec 19, 2018

Appl. No.:

16/225868

Inventors:

- NEW YORK NY, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US
WAYNE FORREST PATTON - DIX HILLS NY, US
JAMES J. DONEGAN - LONG BEACH NY, US

Assignee:

ENZO LIFE SCIENCES, INC. C/0 ENZO BIOCHEM, INC. - NEW YORK NY

International Classification:

G01N 33/92
C07J 9/00
C07J 43/00
C07K 16/44
G01N 33/569
G01N 33/53
C07K 16/18

Abstract:

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

US Patent:

20170219612, Aug 3, 2017

Filed:

Apr 11, 2017

Appl. No.:

15/484754

Inventors:

- NEW YORK NY, US
ROBERT ELLIOT ZIPKIN - WYNNEWOOD PA, US
JEFFREY KROLL ADAMS - FORT WASHINGTON PA, US
WAYNE FORREST PATTON - DIX HILLS NY, US
JAMES J. DONEGAN - LONG BEACH NY, US

Assignee:

ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. - NEW YORK NY

International Classification:

G01N 33/92
C07J 43/00

Abstract:

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

US Patent:

20150104817, Apr 16, 2015

Filed:

Dec 16, 2014

Appl. No.:

14/572133

Inventors:

- NEW YORK NY, US
Robert Elliot Zipkin - Wynnewood PA, US
Jeffrey Kroll Adams - Fort Washington PA, US
Wayne Forrest Patton - Dix Hills NY, US
James J. Donegan - Long Beach NY, US

Assignee:

ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. - New York NY

International Classification:

G01N 33/53

US Classification:

435 792, 435 79

Abstract:

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.